PDCD1 and rheumatoid arthritis: Since PD-1 antagonism pathway genes are in fact involved in T cell activation, which accounts for the therapeutic efficacy of Nivolumab in cancer patients, it is not far-fetched to predict that similar set of T cell genes may show induction after Nivolumab treatment and in autoimmune settings such as RA.